Pharmafile Logo
Pharmafocus logo
Advanced Search

Farnesoid X Receptor

Showing 1 posts of 1 posts found.

Gilead acquires Phenex liver disease drugs

January 7, 2015
Research and Development, Sales and Marketing Farnesoid X Receptor, Gilead, liver, nafld, nash, phenex

Gilead Sciences has acquired Phenex Pharmaceuticals’ development programme for the treatment of serious liver diseases. The US biopharma firm will …

News
The Gateway to Local Adoption Series

Latest content

Care Quality Commission appoints Emily Miles as Chief Executive

July 17, 2026

National survey aims to improve glaucoma care across the UK

July 16, 2026

Phase 3 trials support expanded use of Dysport for migraine prevention

July 15, 2026

Roche secures CE Mark for automated latent tuberculosis blood test

July 14, 2026

ReproNovo Phase 2 fertility study doses first participant

July 10, 2026